Shamburg News · 8-K filed Nov 18, 2026, 8:00 AM EST

Telomir Pharmaceuticals Selects Linical as CRO for Telomir-Zn Phase 1/2 Breast Cancer Trial

TELO · Telomir Pharmaceuticals, Inc.

  • Other event
  • Material agreement
  • Materiality: medium

On November 18, 2026, Telomir Pharmaceuticals announced it selected Linical, a global contract research organization with oncology experience, to support its FDA-cleared Phase 1/2 trial of Telomir-Zn in advanced or metastatic triple-negative breast cancer. The Company executed a Master Services Agreement and clinical trial Work Order with Linical. Clinical initiation is targeted for the first quarter of 2027.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 7.01, 9.01, accession 0001493152-26-052994.

Written from the filing by Shamburg Markets. Figures are as reported by the company.